Market Overview:
The global genetic disorders drug market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of genetic disorders, rising awareness about available treatments, and technological advancements in the field of gene therapy. Based on type, the global genetic disorders drug market is segmented into cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), lysosomal storage disease (LSD), and paroxysmal nocturnal hemoglobinuria (PNH). CF is the most common type of genetic disorder and accounts for a majority share of the global market. Based on application, the clinic segment dominates the global market followed by hospital segments.
Product Definition:
A Genetic Disorder Drug is a medication that is used to treat or prevent genetic disorders. The importance of Genetic Disorders Drugs is that they can help to improve the quality of life for people who are affected by genetic disorders.
Cystic Fibrosis (CF):
Cystic Fibrosis (CF) is a life-shortening genetic disorder caused by mutations in the CF gene that encodes for the cystic fibrosis transmembrane conductance regulator. The disease is characterized by recurrent respiratory infections, chronic pancreatic insufficiency, and progressive lung damage. According to data published in 2017 by Orphanet, there are 30-40 thousand patients with Cystic Fibrosis across the globe.
Duchenne Muscular Dystrophy (DMD):
DMD is a progressive, degenerative disorder of the muscular dystrophies that primarily affects males. The disease has an incidence rate of 1 per 100,000 live births and is more commonly found in the developed countries. However, it can also be seen in developing nations due to improved diagnostics facilities and awareness about such rare disorders among parents & physicians.
Application Insights:
The hospital application segment dominated the global genetic disorders drug market in 2017, accounting for over 69.0% share of the total revenue. The growing number of clinical research studies and increasing prevalence of rare diseases are some of the key factors contributing to the large share held by this segment. For instance, according to a study published in NCBI in 2018, there are more than 300 million people worldwide suffering from rare diseases and it is expected that by 2030, this number will increase to 400 million due to rising healthcare costs and improved living standards. This trend is projected to boost demand for expensive drugs with high therapeutic index such as biologics & gene therapies which would subsequently fuel growth during forecast years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of patients suffering from genetic disorders, increased R&D investments by pharmaceutical companies, and high healthcare expenditure in this region. Moreover, increasing awareness about these conditions is expected to fuel market growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare spending by various governments and rising patient awareness levels regarding available treatment options for genetic diseases. The availability of effective therapies at low costs coupled with growing demand for generic drugs will also contribute toward regional growth over the next eight years.
Growth Factors:
- Increasing prevalence of genetic disorders: The global prevalence of genetic disorders is increasing at a rapid pace. This is primarily attributed to the rising incidence of lifestyle-associated diseases and the growing awareness about genetic disorders among people.
- Advances in genomics and proteomics: The field of genomics and proteomics is witnessing rapid advancements, which is aiding in the diagnosis and treatment of various genetic disorders. This is resulting in an increase in demand for Genetic Disorders Drugs worldwide.
- Growing investments by pharmaceutical companies: Pharmaceutical companies are investing heavily in research and development activities for the development of novel drugs for treating various types of genetic disorders. This is propelling the growth prospects for the Genetic Disorders Drug market globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Genetic Disorders Drug Market Research Report
By Type
Cystic Fibrosis (CF), Duchenne Muscular Dystrophy (DMD), Lysosomal Storage Disease (LSD), Paroxysmal Nocturnal Hemoglobinuria (PNH)
By Application
Clinic, Hospital
By Companies
Sanofi, Vertex, Shire, Amgen, GW Pharmaceuticals, Pfizer, BioMarin, Sarepta
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Genetic Disorders Drug Market Report Segments:
The global Genetic Disorders Drug market is segmented on the basis of:
Types
Cystic Fibrosis (CF), Duchenne Muscular Dystrophy (DMD), Lysosomal Storage Disease (LSD), Paroxysmal Nocturnal Hemoglobinuria (PNH)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Vertex
- Shire
- Amgen
- GW Pharmaceuticals
- Pfizer
- BioMarin
- Sarepta
Highlights of The Genetic Disorders Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cystic Fibrosis (CF)
- Duchenne Muscular Dystrophy (DMD)
- Lysosomal Storage Disease (LSD)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- By Application:
- Clinic
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genetic Disorders Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A drug that is used to treat a genetic disorder is a medication prescribed by a doctor. Drugs used to treat genetic disorders can help improve the symptoms of the disorder, such as improving muscle function or reducing seizures.
Some of the key players operating in the genetic disorders drug market are Sanofi, Vertex, Shire, Amgen, GW Pharmaceuticals, Pfizer, BioMarin, Sarepta.
The genetic disorders drug market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genetic Disorders Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Genetic Disorders Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Genetic Disorders Drug Market - Supply Chain
4.5. Global Genetic Disorders Drug Market Forecast
4.5.1. Genetic Disorders Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Genetic Disorders Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Genetic Disorders Drug Market Absolute $ Opportunity
5. Global Genetic Disorders Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Genetic Disorders Drug Market Size and Volume Forecast by Type
5.3.1. Cystic Fibrosis (CF)
5.3.2. Duchenne Muscular Dystrophy (DMD)
5.3.3. Lysosomal Storage Disease (LSD)
5.3.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Genetic Disorders Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Genetic Disorders Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Genetic Disorders Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Genetic Disorders Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Genetic Disorders Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Genetic Disorders Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Genetic Disorders Drug Demand Share Forecast, 2019-2026
9. North America Genetic Disorders Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Genetic Disorders Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Genetic Disorders Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Genetic Disorders Drug Market Size and Volume Forecast by Type
9.7.1. Cystic Fibrosis (CF)
9.7.2. Duchenne Muscular Dystrophy (DMD)
9.7.3. Lysosomal Storage Disease (LSD)
9.7.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Genetic Disorders Drug Demand Share Forecast, 2019-2026
10. Latin America Genetic Disorders Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Genetic Disorders Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Genetic Disorders Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Genetic Disorders Drug Market Size and Volume Forecast by Type
10.7.1. Cystic Fibrosis (CF)
10.7.2. Duchenne Muscular Dystrophy (DMD)
10.7.3. Lysosomal Storage Disease (LSD)
10.7.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Genetic Disorders Drug Demand Share Forecast, 2019-2026
11. Europe Genetic Disorders Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Genetic Disorders Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Genetic Disorders Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Genetic Disorders Drug Market Size and Volume Forecast by Type
11.7.1. Cystic Fibrosis (CF)
11.7.2. Duchenne Muscular Dystrophy (DMD)
11.7.3. Lysosomal Storage Disease (LSD)
11.7.4. Paroxysmal Nocturnl Hemoglobinuria (PNH)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Genetic Disorders Drug Demand Share, 2019-2026
12. Asia Pacific Genetic Disorders Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Genetic Disorders Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Genetic Disorders Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Genetic Disorders Drug Market Size and Volume Forecast by Type
12.7.1. Cystic Fibrosis (CF)
12.7.2. Duchenne Muscular Dystrophy (DMD)
12.7.3. Lysosomal Storage Disease (LSD)
12.7.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Genetic Disorders Drug Demand Share, 2019-2026
13. Middle East & Africa Genetic Disorders Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Genetic Disorders Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Genetic Disorders Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Genetic Disorders Drug Market Size and Volume Forecast by Type
13.7.1. Cystic Fibrosis (CF)
13.7.2. Duchenne Muscular Dystrophy (DMD)
13.7.3. Lysosomal Storage Disease (LSD)
13.7.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Genetic Disorders Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Genetic Disorders Drug Market: Market Share Analysis
14.2. Genetic Disorders Drug Distributors and Customers
14.3. Genetic Disorders Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Vertex
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shire
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Amgen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GW Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. BioMarin
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sarepta
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
